{
    "root": "607b4223-661d-45e0-8209-99c5ba62d5c0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "NOURIANZ",
    "value": "20250520",
    "ingredients": [
        {
            "name": "istradefylline",
            "code": "2GZ0LIK7T4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134726"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "Microcrystalline Cellulose",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "Carnauba Wax",
            "code": "R12CBM0EIZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_73702"
        }
    ],
    "indications": {
        "text": "nourianz indicated adjunctive treatment levodopa/carbidopa adult patients parkinson 's disease ( pd ) experiencing `` `` episodes .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended 20 mg orally daily . may increased maximum 40 mg daily ( 2.1 ) . may taken without food ( 2.1 ) . patients hepatic impairment : maximum recommended moderate hepatic impairment 20 mg daily ; nourianz patients severe hepatic impairment avoided ( 2.4 , 8.7 ) . patients smoke 20 cigarettes per day ( equivalent another tobacco product ) : recommended 40 mg daily ( 2.5 , 8.8 ) .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing \"off\" episodes.",
    "contraindications_original": "The recommended dosage is 20 mg orally once daily. The dosage may be increased to a maximum of 40 mg once daily ( 2.1 ). May be taken with or without food ( 2.1 ). Patients with hepatic impairment: Maximum recommended dosage with moderate hepatic impairment is 20 mg once daily; use of NOURIANZ in patients with severe hepatic impairment should be avoided ( 2.4 , 8.7 ). Patients who smoke 20 or more cigarettes per day (or the equivalent of another tobacco product): Recommended dosage is 40 mg once daily ( 2.5 , 8.8 ).",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "NOURIANZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134726"
        }
    ]
}